 | • レポートコード：MRC2Q12-02358 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：化学&材料 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、リラグルチドAPIのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 リラグルチドAPIのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 リラグルチドAPIの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 リラグルチドAPIのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのリラグルチドAPIの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のリラグルチドAPIの売上および2028年までの予測に焦点を当てています。 リラグルチドAPIのグローバル主要企業には、Suzhou Tianma Pharma Group、Chengdu Shengnuo Biopharm、Hangzhou Jiuyuan Gene Engineering、Hybio Pharmaceutical、Dr. Reddy's Laboratories、Rochem International Inc、ChemWerth Inc、Bachem AG、CBL- Chemical and Biopharmaceutical Laboratories、AmbioPharm、Piramal Pharma Solutions、ALP Pharm、Amphastar Pharmaceuticals、Amuna Pharmaceuticals LLP、Anthem Biosciences、Aurobindo Pharma Limited、Fresenius SE & Co. KGaAなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 リラグルチドAPI市場は、タイプとアプリケーションによって区分されます。世界のリラグルチドAPI市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 0.98、0.99、0.995、その他 【アプリケーション別セグメント】 注射剤、錠剤、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - リラグルチドAPI製品概要 - タイプ別市場（0.98、0.99、0.995、その他） - アプリケーション別市場（注射剤、錠剤、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のリラグルチドAPI販売量予測2017-2028 - 世界のリラグルチドAPI売上予測2017-2028 - リラグルチドAPIの地域別販売量 - リラグルチドAPIの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別リラグルチドAPI販売量 - 主要メーカー別リラグルチドAPI売上 - 主要メーカー別リラグルチドAPI価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（0.98、0.99、0.995、その他） - リラグルチドAPIのタイプ別販売量 - リラグルチドAPIのタイプ別売上 - リラグルチドAPIのタイプ別価格 ・アプリケーション別市場規模（注射剤、錠剤、その他） - リラグルチドAPIのアプリケーション別販売量 - リラグルチドAPIのアプリケーション別売上 - リラグルチドAPIのアプリケーション別価格 ・北米市場 - 北米のリラグルチドAPI市場規模（タイプ別、アプリケーション別） - 主要国別のリラグルチドAPI市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのリラグルチドAPI市場規模（タイプ別、アプリケーション別） - 主要国別のリラグルチドAPI市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のリラグルチドAPI市場規模（タイプ別、アプリケーション別） - 主要国別のリラグルチドAPI市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のリラグルチドAPI市場規模（タイプ別、アプリケーション別） - 主要国別のリラグルチドAPI市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのリラグルチドAPI市場規模（タイプ別、アプリケーション別） - 主要国別のリラグルチドAPI市場規模（トルコ、サウジアラビア） ・企業情報 Suzhou Tianma Pharma Group、Chengdu Shengnuo Biopharm、Hangzhou Jiuyuan Gene Engineering、Hybio Pharmaceutical、Dr. Reddy's Laboratories、Rochem International Inc、ChemWerth Inc、Bachem AG、CBL- Chemical and Biopharmaceutical Laboratories、AmbioPharm、Piramal Pharma Solutions、ALP Pharm、Amphastar Pharmaceuticals、Amuna Pharmaceuticals LLP、Anthem Biosciences、Aurobindo Pharma Limited、Fresenius SE & Co. KGaA ・産業チェーン及び販売チャネル分析 - リラグルチドAPIの産業チェーン分析 - リラグルチドAPIの原材料 - リラグルチドAPIの生産プロセス - リラグルチドAPIの販売及びマーケティング - リラグルチドAPIの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - リラグルチドAPIの産業動向 - リラグルチドAPIのマーケットドライバー - リラグルチドAPIの課題 - リラグルチドAPIの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Liraglutide API estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Liraglutide API is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Liraglutide API is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Liraglutide API is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Liraglutide API include Suzhou Tianma Pharma Group, Chengdu Shengnuo Biopharm, Hangzhou Jiuyuan Gene Engineering, Hybio Pharmaceutical, Dr. Reddy’s Laboratories, Rochem International Inc, ChemWerth Inc, Bachem AG and CBL- Chemical and Biopharmaceutical Laboratories, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
In terms of production side, this report researches the Liraglutide API production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Liraglutide API by region (region level and country level), by company, by Purity and by Application. from 2017 to 2022 and forecast to 2028.
Report Scope
This latest report researches the industry structure, capacity, production, sales (consumption), revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Liraglutide API manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Liraglutide API market. Further, it explains the major drivers and regional dynamics of the global Liraglutide API market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Suzhou Tianma Pharma Group
Chengdu Shengnuo Biopharm
Hangzhou Jiuyuan Gene Engineering
Hybio Pharmaceutical
Dr. Reddy’s Laboratories
Rochem International Inc
ChemWerth Inc
Bachem AG
CBL- Chemical and Biopharmaceutical Laboratories
AmbioPharm
Piramal Pharma Solutions
ALP Pharm
Amphastar Pharmaceuticals
Amuna Pharmaceuticals LLP
Anthem Biosciences
Aurobindo Pharma Limited
Fresenius SE & Co. KGaA
Market Segments
This report has explored the key segments: by Purity and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on production, price, and value for the period 2017-2028.
Liraglutide API Segment by Purity
0.98
0.99
0.995
Others
Liraglutide API Segment by Application
Injection
Pills
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. This report analyzes the Liraglutide API production by region/country, and the sales (consumption) by region/country. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Liraglutide API market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Liraglutide API, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Liraglutide API, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Liraglutide API, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Liraglutide API sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Liraglutide API market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Liraglutide API sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Suzhou Tianma Pharma Group, Chengdu Shengnuo Biopharm, Hangzhou Jiuyuan Gene Engineering, Hybio Pharmaceutical, Dr. Reddy’s Laboratories, Rochem International Inc, ChemWerth Inc, Bachem AG and CBL- Chemical and Biopharmaceutical Laboratories, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Liraglutide API capacity, production/output of global and key producers (regions/countries). It provides a quantitative analysis of the capacity, production, and development potential of each producer in the next six years.
Chapter 3: Sales (consumption), revenue of Liraglutide API in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Liraglutide API manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by purity, by application and by country, sales and revenue for each segment.
Chapter 8: Europe by purity, by application and by country, sales and revenue for each segment.
Chapter 9: Asia Pacific by purity, by application and by country, sales and revenue for each segment.
Chapter 10: Latin America by purity, by application and by country, sales and revenue for each segment.
Chapter 11: Middle East and Africa by purity, by application and by country, sales and revenue for each segment.
Chapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Liraglutide API sales, revenue, price, gross margin, and recent development, etc.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 15: The main points and conclusions of the report.
1 Study Coverage
1.1 Liraglutide API Product Introduction
1.2 Market by Purity
1.2.1 Global Liraglutide API Market Size by Purity, 2017 VS 2021 VS 2028
1.2.2 0.98
1.2.3 0.99
1.2.4 0.995
1.2.5 Others
1.3 Market by Application
1.3.1 Global Liraglutide API Market Size by Application, 2017 VS 2021 VS 2028
1.3.2 Injection
1.3.3 Pills
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Liraglutide API Production
2.1 Global Liraglutide API Production Capacity (2017-2028)
2.2 Global Liraglutide API Production by Region: 2017 VS 2021 VS 2028
2.3 Global Liraglutide API Production by Region
2.3.1 Global Liraglutide API Historic Production by Region (2017-2022)
2.3.2 Global Liraglutide API Forecasted Production by Region (2023-2028)
2.4 North America
2.5 Europe
2.6 China
2.7 Japan
3 Global Liraglutide API Sales in Volume & Value Estimates and Forecasts
3.1 Global Liraglutide API Sales Estimates and Forecasts 2017-2028
3.2 Global Liraglutide API Revenue Estimates and Forecasts 2017-2028
3.3 Global Liraglutide API Revenue by Region: 2017 VS 2021 VS 2028
3.4 Global Liraglutide API Sales by Region
3.4.1 Global Liraglutide API Sales by Region (2017-2022)
3.4.2 Global Sales Liraglutide API by Region (2023-2028)
3.5 Global Liraglutide API Revenue by Region
3.5.1 Global Liraglutide API Revenue by Region (2017-2022)
3.5.2 Global Liraglutide API Revenue by Region (2023-2028)
3.6 North America
3.7 Europe
3.8 Asia-Pacific
3.9 Latin America
3.10 Middle East & Africa
4 Competition by Manufactures
4.1 Global Liraglutide API Production Capacity by Manufacturers
4.2 Global Liraglutide API Sales by Manufacturers
4.2.1 Global Liraglutide API Sales by Manufacturers (2017-2022)
4.2.2 Global Liraglutide API Sales Market Share by Manufacturers (2017-2022)
4.2.3 Global Top 10 and Top 5 Largest Manufacturers of Liraglutide API in 2021
4.3 Global Liraglutide API Revenue by Manufacturers
4.3.1 Global Liraglutide API Revenue by Manufacturers (2017-2022)
4.3.2 Global Liraglutide API Revenue Market Share by Manufacturers (2017-2022)
4.3.3 Global Top 10 and Top 5 Companies by Liraglutide API Revenue in 2021
4.4 Global Liraglutide API Sales Price by Manufacturers
4.5 Analysis of Competitive Landscape
4.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
4.5.2 Global Liraglutide API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5.3 Global Liraglutide API Manufacturers Geographical Distribution
4.6 Mergers & Acquisitions, Expansion Plans
5 Market Size by Purity
5.1 Global Liraglutide API Sales by Purity
5.1.1 Global Liraglutide API Historical Sales by Purity (2017-2022)
5.1.2 Global Liraglutide API Forecasted Sales by Purity (2023-2028)
5.1.3 Global Liraglutide API Sales Market Share by Purity (2017-2028)
5.2 Global Liraglutide API Revenue by Purity
5.2.1 Global Liraglutide API Historical Revenue by Purity (2017-2022)
5.2.2 Global Liraglutide API Forecasted Revenue by Purity (2023-2028)
5.2.3 Global Liraglutide API Revenue Market Share by Purity (2017-2028)
5.3 Global Liraglutide API Price by Purity
5.3.1 Global Liraglutide API Price by Purity (2017-2022)
5.3.2 Global Liraglutide API Price Forecast by Purity (2023-2028)
6 Market Size by Application
6.1 Global Liraglutide API Sales by Application
6.1.1 Global Liraglutide API Historical Sales by Application (2017-2022)
6.1.2 Global Liraglutide API Forecasted Sales by Application (2023-2028)
6.1.3 Global Liraglutide API Sales Market Share by Application (2017-2028)
6.2 Global Liraglutide API Revenue by Application
6.2.1 Global Liraglutide API Historical Revenue by Application (2017-2022)
6.2.2 Global Liraglutide API Forecasted Revenue by Application (2023-2028)
6.2.3 Global Liraglutide API Revenue Market Share by Application (2017-2028)
6.3 Global Liraglutide API Price by Application
6.3.1 Global Liraglutide API Price by Application (2017-2022)
6.3.2 Global Liraglutide API Price Forecast by Application (2023-2028)
7 North America
7.1 North America Liraglutide API Market Size by Purity
7.1.1 North America Liraglutide API Sales by Purity (2017-2028)
7.1.2 North America Liraglutide API Revenue by Purity (2017-2028)
7.2 North America Liraglutide API Market Size by Application
7.2.1 North America Liraglutide API Sales by Application (2017-2028)
7.2.2 North America Liraglutide API Revenue by Application (2017-2028)
7.3 North America Liraglutide API Sales by Country
7.3.1 North America Liraglutide API Sales by Country (2017-2028)
7.3.2 North America Liraglutide API Revenue by Country (2017-2028)
7.3.3 United States
7.3.4 Canada
8 Europe
8.1 Europe Liraglutide API Market Size by Purity
8.1.1 Europe Liraglutide API Sales by Purity (2017-2028)
8.1.2 Europe Liraglutide API Revenue by Purity (2017-2028)
8.2 Europe Liraglutide API Market Size by Application
8.2.1 Europe Liraglutide API Sales by Application (2017-2028)
8.2.2 Europe Liraglutide API Revenue by Application (2017-2028)
8.3 Europe Liraglutide API Sales by Country
8.3.1 Europe Liraglutide API Sales by Country (2017-2028)
8.3.2 Europe Liraglutide API Revenue by Country (2017-2028)
8.3.3 Germany
8.3.4 France
8.3.5 U.K.
8.3.6 Italy
8.3.7 Russia
9 Asia Pacific
9.1 Asia Pacific Liraglutide API Market Size by Purity
9.1.1 Asia Pacific Liraglutide API Sales by Purity (2017-2028)
9.1.2 Asia Pacific Liraglutide API Revenue by Purity (2017-2028)
9.2 Asia Pacific Liraglutide API Market Size by Application
9.2.1 Asia Pacific Liraglutide API Sales by Application (2017-2028)
9.2.2 Asia Pacific Liraglutide API Revenue by Application (2017-2028)
9.3 Asia Pacific Liraglutide API Sales by Region
9.3.1 Asia Pacific Liraglutide API Sales by Region (2017-2028)
9.3.2 Asia Pacific Liraglutide API Revenue by Region (2017-2028)
9.3.3 China
9.3.4 Japan
9.3.5 South Korea
9.3.6 India
9.3.7 Australia
9.3.8 China Taiwan
9.3.9 Indonesia
9.3.10 Thailand
9.3.11 Malaysia
10 Latin America
10.1 Latin America Liraglutide API Market Size by Purity
10.1.1 Latin America Liraglutide API Sales by Purity (2017-2028)
10.1.2 Latin America Liraglutide API Revenue by Purity (2017-2028)
10.2 Latin America Liraglutide API Market Size by Application
10.2.1 Latin America Liraglutide API Sales by Application (2017-2028)
10.2.2 Latin America Liraglutide API Revenue by Application (2017-2028)
10.3 Latin America Liraglutide API Sales by Country
10.3.1 Latin America Liraglutide API Sales by Country (2017-2028)
10.3.2 Latin America Liraglutide API Revenue by Country (2017-2028)
10.3.3 Mexico
10.3.4 Brazil
10.3.5 Argentina
10.3.6 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Liraglutide API Market Size by Purity
11.1.1 Middle East and Africa Liraglutide API Sales by Purity (2017-2028)
11.1.2 Middle East and Africa Liraglutide API Revenue by Purity (2017-2028)
11.2 Middle East and Africa Liraglutide API Market Size by Application
11.2.1 Middle East and Africa Liraglutide API Sales by Application (2017-2028)
11.2.2 Middle East and Africa Liraglutide API Revenue by Application (2017-2028)
11.3 Middle East and Africa Liraglutide API Sales by Country
11.3.1 Middle East and Africa Liraglutide API Sales by Country (2017-2028)
11.3.2 Middle East and Africa Liraglutide API Revenue by Country (2017-2028)
11.3.3 Turkey
11.3.4 Saudi Arabia
11.3.5 UAE
12 Corporate Profiles
12.1 Suzhou Tianma Pharma Group
12.1.1 Suzhou Tianma Pharma Group Corporation Information
12.1.2 Suzhou Tianma Pharma Group Overview
12.1.3 Suzhou Tianma Pharma Group Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.1.4 Suzhou Tianma Pharma Group Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.1.5 Suzhou Tianma Pharma Group Recent Developments
12.2 Chengdu Shengnuo Biopharm
12.2.1 Chengdu Shengnuo Biopharm Corporation Information
12.2.2 Chengdu Shengnuo Biopharm Overview
12.2.3 Chengdu Shengnuo Biopharm Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.2.4 Chengdu Shengnuo Biopharm Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.2.5 Chengdu Shengnuo Biopharm Recent Developments
12.3 Hangzhou Jiuyuan Gene Engineering
12.3.1 Hangzhou Jiuyuan Gene Engineering Corporation Information
12.3.2 Hangzhou Jiuyuan Gene Engineering Overview
12.3.3 Hangzhou Jiuyuan Gene Engineering Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.3.4 Hangzhou Jiuyuan Gene Engineering Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.3.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
12.4 Hybio Pharmaceutical
12.4.1 Hybio Pharmaceutical Corporation Information
12.4.2 Hybio Pharmaceutical Overview
12.4.3 Hybio Pharmaceutical Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.4.4 Hybio Pharmaceutical Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.4.5 Hybio Pharmaceutical Recent Developments
12.5 Dr. Reddy’s Laboratories
12.5.1 Dr. Reddy’s Laboratories Corporation Information
12.5.2 Dr. Reddy’s Laboratories Overview
12.5.3 Dr. Reddy’s Laboratories Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.5.4 Dr. Reddy’s Laboratories Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.5.5 Dr. Reddy’s Laboratories Recent Developments
12.6 Rochem International Inc
12.6.1 Rochem International Inc Corporation Information
12.6.2 Rochem International Inc Overview
12.6.3 Rochem International Inc Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.6.4 Rochem International Inc Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.6.5 Rochem International Inc Recent Developments
12.7 ChemWerth Inc
12.7.1 ChemWerth Inc Corporation Information
12.7.2 ChemWerth Inc Overview
12.7.3 ChemWerth Inc Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.7.4 ChemWerth Inc Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.7.5 ChemWerth Inc Recent Developments
12.8 Bachem AG
12.8.1 Bachem AG Corporation Information
12.8.2 Bachem AG Overview
12.8.3 Bachem AG Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.8.4 Bachem AG Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.8.5 Bachem AG Recent Developments
12.9 CBL- Chemical and Biopharmaceutical Laboratories
12.9.1 CBL- Chemical and Biopharmaceutical Laboratories Corporation Information
12.9.2 CBL- Chemical and Biopharmaceutical Laboratories Overview
12.9.3 CBL- Chemical and Biopharmaceutical Laboratories Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.9.4 CBL- Chemical and Biopharmaceutical Laboratories Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.9.5 CBL- Chemical and Biopharmaceutical Laboratories Recent Developments
12.10 AmbioPharm
12.10.1 AmbioPharm Corporation Information
12.10.2 AmbioPharm Overview
12.10.3 AmbioPharm Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.10.4 AmbioPharm Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.10.5 AmbioPharm Recent Developments
12.11 Piramal Pharma Solutions
12.11.1 Piramal Pharma Solutions Corporation Information
12.11.2 Piramal Pharma Solutions Overview
12.11.3 Piramal Pharma Solutions Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.11.4 Piramal Pharma Solutions Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.11.5 Piramal Pharma Solutions Recent Developments
12.12 ALP Pharm
12.12.1 ALP Pharm Corporation Information
12.12.2 ALP Pharm Overview
12.12.3 ALP Pharm Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.12.4 ALP Pharm Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.12.5 ALP Pharm Recent Developments
12.13 Amphastar Pharmaceuticals
12.13.1 Amphastar Pharmaceuticals Corporation Information
12.13.2 Amphastar Pharmaceuticals Overview
12.13.3 Amphastar Pharmaceuticals Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.13.4 Amphastar Pharmaceuticals Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.13.5 Amphastar Pharmaceuticals Recent Developments
12.14 Amuna Pharmaceuticals LLP
12.14.1 Amuna Pharmaceuticals LLP Corporation Information
12.14.2 Amuna Pharmaceuticals LLP Overview
12.14.3 Amuna Pharmaceuticals LLP Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.14.4 Amuna Pharmaceuticals LLP Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.14.5 Amuna Pharmaceuticals LLP Recent Developments
12.15 Anthem Biosciences
12.15.1 Anthem Biosciences Corporation Information
12.15.2 Anthem Biosciences Overview
12.15.3 Anthem Biosciences Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.15.4 Anthem Biosciences Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.15.5 Anthem Biosciences Recent Developments
12.16 Aurobindo Pharma Limited
12.16.1 Aurobindo Pharma Limited Corporation Information
12.16.2 Aurobindo Pharma Limited Overview
12.16.3 Aurobindo Pharma Limited Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.16.4 Aurobindo Pharma Limited Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.16.5 Aurobindo Pharma Limited Recent Developments
12.17 Fresenius SE & Co. KGaA
12.17.1 Fresenius SE & Co. KGaA Corporation Information
12.17.2 Fresenius SE & Co. KGaA Overview
12.17.3 Fresenius SE & Co. KGaA Liraglutide API Sales, Price, Revenue and Gross Margin (2017-2022)
12.17.4 Fresenius SE & Co. KGaA Liraglutide API Product Model Numbers, Pictures, Descriptions and Specifications
12.17.5 Fresenius SE & Co. KGaA Recent Developments
13 Industry Chain and Sales Channels Analysis
13.1 Liraglutide API Industry Chain Analysis
13.2 Liraglutide API Key Raw Materials
13.2.1 Key Raw Materials
13.2.2 Raw Materials Key Suppliers
13.3 Liraglutide API Production Mode & Process
13.4 Liraglutide API Sales and Marketing
13.4.1 Liraglutide API Sales Channels
13.4.2 Liraglutide API Distributors
13.5 Liraglutide API Customers
14 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
14.1 Liraglutide API Industry Trends
14.2 Liraglutide API Market Drivers
14.3 Liraglutide API Market Challenges
14.4 Liraglutide API Market Restraints
15 Key Finding in The Global Liraglutide API Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer